Results 41 to 50 of about 511,582 (401)
Treatment Methods Dry Form of Age Macular Degeneration — History and Prospects. Review
Oftalʹmologiâ, 2023 Age related macular degeneration is a leading cause of vision loss and an increasing problem of disability throughout the world among adults. That revue covers historical points, risk factors, pathogenesis, classification and current treatment ways of ...
A. N. Kulikov +2 more
doaj +1 more source
EMT and EndMT: Emerging Roles in Age-Related Macular Degeneration
International Journal of Molecular Sciences, 2020 Epithelial–mesenchymal transition (EMT) and endothelial–mesenchymal transition (EndMT) are physiological processes required for normal embryogenesis. However, these processes can be hijacked in pathological conditions to facilitate tissue fibrosis and ...
Daisy Y. Shu +2 more
semanticscholar +1 more source
Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article [PDF]
, 2017 Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD).
Elena Gusson +8 more
core +1 more source
New Frontiers in Retina: highlights of the 2020 angiogenesis, exudation and degeneration symposium
International Journal of Retina and Vitreous, 2020 We summarize the most important findings presented at the 2020 angiogenesis, exudation and degeneration symposium in five topic areas: (1) epidemiology of retinal vascular disease and macular degeneration; (2) dry AMD and geographic atrophy; (3 ...
Carmen A. Puliafito, Charles C. Wykoff
doaj +1 more source
Recent advances of exosomes in age-related macular degeneration
Frontiers in Pharmacology, 2023 Exosomes are 30–150 nm extracellular vesicles that are secreted by almost all types of cells. Exosomes contain a variety of biologically active substances, such as proteins, nucleic acids, and lipids, and are important in the intercellular communication ...
Feng Gu, Jiyu Jiang, Peng Sun
doaj +1 more source
Nature Genetics, 2015 Advanced age-related macular degeneration (AMD) is the leading cause of blindness in the elderly, with limited therapeutic options. Here we report on a study of >12 million variants, including 163,714 directly genotyped, mostly rare, protein-altering ...
F. Grassmann, Shritoma Sengupta
semanticscholar +1 more source
Association of Retinal Vascular Caliber and Age-Related Macular Degeneration in Patients With the Acquired Immunodeficiency Syndrome. [PDF]
, 2018 PurposeTo evaluate the relationship between retinal vascular caliber and AMD in patients with AIDS.MethodsParticipants enrolled in the Longitudinal Study of the Ocular Complications of AIDS had retinal photographs taken at enrollment.
Danis, Ronald P +4 more
core +1 more source
Health Technology Assessment, 2022 Background: Neovascular age-related macular degeneration is a leading cause of sight loss, and early detection and treatment is important. For patients with neovascular age-related macular degeneration in one eye, it is usual practice to monitor the ...
Katie Banister +11 more
doaj +1 more source
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
New England Journal of Medicine, 2011 BACKGROUND Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data ...
Daniel F. Martin +5 more
semanticscholar +1 more source
Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case [PDF]
, 2004 AIM: To estimate the potential cost effectiveness of photodynamic therapy (PDT) with verteporfin in the UK setting. METHODS: Using data from a variety of sources a Markov model was built to produce estimates of the cost effectiveness (incremental cost ...
Drummond, M., Fenn, P., Smith, D.H.
core +2 more sources